Aim: The purpose of this study was to evaluate the levels of carcinoembryonic antigen (CEA) and lipid profile [total cholesterol (TC), serum triglycerides (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and very-low-density lipoprotein (VLDL)] in patients with breast cancer and compared them with healthy individuals as a control group. Materials and methods: In the present study, 100 women included 50 breast cancer patients with age >18 years and 50 controls with similar age range were assessed for CEA and lipid profile. Result: The present study has demonstrated that the levels of CEA, TC, LDL, VLDL, and TG were significantly higher and the levels of HDL were lower in patients with breast cancer. Conclusion: The study concluded that CEA levels were higher in the case group and it is one of the most commonly expressed biological markers in breast cancer patients and when lipid profile was compared between breast cancer patients and the control group, then, TC, LDL, VLDL, and TG were significantly higher and the levels of HDL were lower in patients with breast cancer.
Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information. J Natl Cancer Inst 2010;102(21):1618–1627. DOI: 10.1093/jnci/djq388.
Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol 2018;4(11):1553–1568. DOI: 10.1001/jamaoncol.2018.2706.
Global cancer statistics. Cancer J Clin 2011;61(2):69–90. DOI: 10.3322/caac.20107.
Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424. DOI: 10.3322/caac.21492.
Evaluation of serum adenosine Deaminase and retinol in patients with laryngeal cancer. Indian J Pharm Biol Res 2013;1(4):30–34. DOI: 10.30750/ijpbr.1.4.6.
The possible role of tumor antigen CA 15-3, CEA and ferritin in malignant and benign disease. J Health Sci 2012(2):138–143. DOI: 10.17532/jhsci.2012.52.
Levels of CEA and ca 19-9 in the sera and peritoneal cavity in patients with gastric and pancreatic cancers. Acta Cir Bras 2012;27(6):410–416. DOI: 10.1590/S0102-86502012000600009.
Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer. PLoS One 2015;10(7):e0133830. DOI: 10.1371/journal.pone.0133830.
CEA monitoring in colorectal cancer.what you should know. Oncology (Williston Park) 2006;20(6):579–588., 594, 596 passim.
Comparison of serum lipid profiles between normal controls and breast cancer patients. J Lab Physicians 2013;5(1):38–41. DOI: 10.4103/0974-2727.115934.
Diabetes and breast cancer risk: a meta-analysis. Br J Cancer 2012;107(9):1608–1617. DOI: 10.1038/bjc.2012.414.
Prognostic markers in triple-negative breast cancer. Cancer 2007;109(1):25–32. DOI: 10.1002/cncr.22381.
Plasma von Willebrand factor level as a prognostic indicator of patients with metastatic colorectal carcinoma. World J Gastroenterol 2005;11(14):2166–2170. DOI: 10.3748/wjg.v11.i14.2166.
Role of serum Carcinoembryonic antigen (CEA) as a tumor marker in breast cancer. Int J Adv Med Health Res 2014;1(2):57–60. DOI: 10.4103/2349-4220.148002.
Clinicopathological and prognostic significance of cancer antigen 15-3 and Carcinoembryonic antigen in breast cancer: a meta-analysis including 12,993 patients. Dis Markers 2018;2018:9863092. DOI: 10.1155/2018/9863092.
Serum lipid profile of breast cancer patients in Kashmir. J Investig Biochem 2013;2(1):26–31. DOI: 10.5455/jib.20121125075314.
The role of developing breast cancer in alteration of serum lipid profile. J Res Med Sci 2012;17(6):562–565.